Allurion Shares Rise 68% After Weight Loss Study News

Dow Jones

24 Jan

By Stephen Nakrosis

Shares of Allurion Technologies were trading higher in the after-hours market following news the company would initiate a clinical study on the combination of certain weight-loss drugs and its Allurion program with the goal of improving muscle mass.

In Thursday's after-hours market, the company's shares had risen 68% to trade at $6.24. Volume in the late session topped 4.3 million shares. Shares finished the day's regular session with a 21% gain at $3.70.

Allurion said it planned to study GLP-1 agonists in combination with its Allurion Program. The company said previous studies in patients undergoing GLP-1 therapy showed reductions in lean mass as part of the overall weight loss. Allurion added previous studies of patients treated with the Allurion Balloon in combination with the Allurion Virtual Care Suite demonstrated outcomes in which patients lose weight while maintaining, and in some cases, increasing, muscle mass.

Shantanu Gaur, the founder and chief executive of Allurion, said the goal of the study would be to prove that combining the Allurion Balloon and Allurion Virtual Care Suite with GLP-1 therapy would lead to patients losing significant weight while increasing muscle mass and improving overall body composition.

Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

(END) Dow Jones Newswires

January 23, 2025 18:22 ET (23:22 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2505351078"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2505351078\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2505351078?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-24 07:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2505351078","market":"sh","top_or_hot":-1,"title":"Allurion Shares Rise 68% After Weight Loss Study News","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Stephen Nakrosis \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of Allurion Technologies were trading higher in the after-hours market following news the company would initiate a clinical study on the combination of certain weight-loss drugs and its Allurion program with the goal of improving muscle mass. \n</p>\n<p>\n  In Thursday's after-hours market, the company's shares had risen 68% to trade at $6.24. Volume in the late session topped 4.3 million shares. Shares finished the day's regular session with a 21% gain at $3.70. \n</p>\n<p>\n  Allurion said it planned to study GLP-1 agonists in combination with its Allurion Program. The company said previous studies in patients undergoing GLP-1 therapy showed reductions in lean mass as part of the overall weight loss. Allurion added previous studies of patients treated with the Allurion Balloon in combination with the Allurion Virtual Care Suite demonstrated outcomes in which patients lose weight while maintaining, and in some cases, increasing, muscle mass. \n</p>\n<p>\n  Shantanu Gaur, the founder and chief executive of Allurion, said the goal of the study would be to prove that combining the Allurion Balloon and Allurion Virtual Care Suite with GLP-1 therapy would lead to patients losing significant weight while increasing muscle mass and improving overall body composition. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Stephen Nakrosis at stephen.nakrosis@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 23, 2025 18:22 ET (23:22 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Allurion Shares Rise 68% After Weight Loss Study News</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAllurion Shares Rise 68% After Weight Loss Study News\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-01-24 07:22</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Stephen Nakrosis \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of Allurion Technologies were trading higher in the after-hours market following news the company would initiate a clinical study on the combination of certain weight-loss drugs and its Allurion program with the goal of improving muscle mass. \n</p>\n<p>\n  In Thursday's after-hours market, the company's shares had risen 68% to trade at $6.24. Volume in the late session topped 4.3 million shares. Shares finished the day's regular session with a 21% gain at $3.70. \n</p>\n<p>\n  Allurion said it planned to study GLP-1 agonists in combination with its Allurion Program. The company said previous studies in patients undergoing GLP-1 therapy showed reductions in lean mass as part of the overall weight loss. Allurion added previous studies of patients treated with the Allurion Balloon in combination with the Allurion Virtual Care Suite demonstrated outcomes in which patients lose weight while maintaining, and in some cases, increasing, muscle mass. \n</p>\n<p>\n  Shantanu Gaur, the founder and chief executive of Allurion, said the goal of the study would be to prove that combining the Allurion Balloon and Allurion Virtual Care Suite with GLP-1 therapy would lead to patients losing significant weight while increasing muscle mass and improving overall body composition. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Stephen Nakrosis at stephen.nakrosis@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 23, 2025 18:22 ET (23:22 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4192","symbol_name":"特殊消费者服务","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2505351078","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2505351078","pubTimestamp":1737674520,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Allurion Technologies were trading higher in the after-hours market following news the company would initiate a clinical study on the combination of certain weight-loss drugs and its Allurion program with the goal of improving muscle mass.In Thursday's after-hours market, the company's shares had risen 68% to trade at $6.24. Volume in the late session topped 4.3 million shares. Shares finished the day's regular session with a 21% gain at $3.70.Allurion said it planned to study GLP-1 agonists in combination with its Allurion Program. The company said previous studies in patients undergoing GLP-1 therapy showed reductions in lean mass as part of the overall weight loss. Allurion added previous studies of patients treated with the Allurion Balloon in combination with the Allurion Virtual Care Suite demonstrated outcomes in which patients lose weight while maintaining, and in some cases, increasing, muscle mass.Shantanu Gaur, the founder and chief executive of Allurion, said the ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4192":"特殊消费者服务","ALUR":"ALLURION TECHNOLOGIES"},"translate_title":"减肥研究消息公布后Allurion股价上涨68%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALUR":0.9},"content_text":"By Stephen Nakrosis \n\n\n \n\n\n  Shares of Allurion Technologies were trading higher in the after-hours market following news the company would initiate a clinical study on the combination of certain weight-loss drugs and its Allurion program with the goal of improving muscle mass. \n\n\n  In Thursday's after-hours market, the company's shares had risen 68% to trade at $6.24. Volume in the late session topped 4.3 million shares. Shares finished the day's regular session with a 21% gain at $3.70. \n\n\n  Allurion said it planned to study GLP-1 agonists in combination with its Allurion Program. The company said previous studies in patients undergoing GLP-1 therapy showed reductions in lean mass as part of the overall weight loss. Allurion added previous studies of patients treated with the Allurion Balloon in combination with the Allurion Virtual Care Suite demonstrated outcomes in which patients lose weight while maintaining, and in some cases, increasing, muscle mass. \n\n\n  Shantanu Gaur, the founder and chief executive of Allurion, said the goal of the study would be to prove that combining the Allurion Balloon and Allurion Virtual Care Suite with GLP-1 therapy would lead to patients losing significant weight while increasing muscle mass and improving overall body composition. \n\n\n \n\n\n  Write to Stephen Nakrosis at stephen.nakrosis@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 23, 2025 18:22 ET (23:22 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}